North America Is Dominating Non-Invasive Prenatal Testing Industry

The non-invasive prenatal testing market was valued at USD 3,987.1 million in 2021 and will grow at a rate of about 9.8% during 2021–2030, reaching USD 9,229.2 million by 2030, according to P&S Intelligence.

To learn more about this report: https://bit.ly/41myShv

This development can be credited to the growing occurrence of chromosomal oddities and the increasing need for early discovery approaches. Around, 14% of stillbirths are because of inherited illnesses in pregnant women in the age group of <24 years and the count increases to 38% in women 40–45 years of age.

Of every genetic abnormality, Trisomy 21 had the highest share. Its yearly occurrence is 1 in 800 newborns, which made it the most-frequent chromosomal abnormality in the U.S. In out-and-out terms, in the U.S., more than 5,000 children are born with Trisomy 21 each year.

In 2021, North America had the highest revenue share, of approximately 45%, in the non-invasive prenatal testing market. This can be credited to the robust healthcare infrastructure and technological improvements in the area of diagnostics.

The U.S. is dominating North America and is also projected to develop with a CAGR of 8%, owing to the robust financial backing. Mainly because of the growing occurrence of chromosomal irregularities in the U.S. has led to an increase in the need for prenatal testing.

Since the U.S. offers progressive tests for hereditary conditions, it dominates the regional industry. Additionally, the whole-genome next-generation sequencing technology is being utilized for the purpose in Canada and the U.S. as it provides earlier and more-precise results.

In 2021, the consumables category had the largest share, of more than 60%, because of the presence of a high number of players offering consumables, such as reagents, disposables, and assay kits. The largest share is also credited to the enhancements in the tests for NIPT and a high number of sanctions to numerous assays.

Hence, the growing occurrence of chromosomal oddities and the increasing need for early discovery approaches are the major factors propelling the non-invasive prenatal testing industry.